Close Menu

At a conference yesterday, Merck's Merv Turner said big pharma's problems are due to researchers, reports Science Insider. "Seventy-five cents of every dollar we spend on R&D goes to fund failure," Turner said. He added that Merck is undergoing "painful" restructuring after acquiring Schering-Plough and that one area that will likely be pared down is late-stage drug development -- though "nothing's safe from cuts."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

Apr
20
Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Apr
28
Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

May
04
Sponsored by
Akoya Biosciences

Recently developed technologies for digital imaging and highly multiplexed immunohistochemistry (mIHC) advancing the field of histology into a quantitative era, allowing for more complex descriptions of tissue architecture.